Skip to main content

TG Therapeutics, Inc. (TGTX) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Biotechnology

Sell if holding. At $39.11, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole-source supply chain.

TG Therapeutics is a commercial-stage biotech with one FDA-approved product, BRIUMVI (ublituximab-xiiy) for relapsing forms of MS, commercially launched in the U.S. in January 2023. Ex-U.S. rights are licensed to Neuraxpharm (deal up to $645M plus tiered royalties up to 30%).... Read more

$39.11+5.9% A.UpsideScore 6.3/10#15 of 157 Biotechnology
QualityF-score6 / 9FCF yield-0.50%
Stop $36.67Target $41.76(analyst − 13%)A.R:R 0.4:1
Analyst target$48.00+22.7%7 analysts
$41.76our TP
$39.11price
$48.00mean
$17
$70

Sell if holding. At $39.11, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole-source supply chain. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 6.3/10, moderate confidence.

Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 76d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.

Val6.5Qual7.3Grw10.0Mom3.0Sent6.6Ins5.0Peer5.9Tech5.5Risk4.66.3OVERALL

Recent Developments — TG Therapeutics, Inc.

Latest news

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
V7 quality resilience bonus: +0.2 (Q=7.3 in RISK_OFF)
Sector modifier (Healthcare): +0.5
High-quality business
Risks
Concentration risk — Product: BRIUMVI
Concentration risk — Supplier: sole-source supply chain
Thin upside margin: 5.9%

Key Metrics

P/E (TTM)13.8
P/E (Fwd)14.5
Mkt Cap$6.0B
EV/EBITDA39.0
Profit Mgn66.0%
ROE112.6%
Rev Growth69.6%
Beta1.68
DividendNone
Rating analysts15

Quality Signals

Piotroski F6/9MoatWideCompounder✓

Options Flow

P/C0.69bullish
IV53%elevated

Concentration Risks(10-K Item 1A)

  • HIGHProductBRIUMVI
    10-K Item 1: 'TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis'
  • HIGHSuppliersole-source supply chain
    10-K Item 1A: 'The third parties upon whom we rely for the supply of starting materials, intermediates, active pharmaceutical ingredient (API)/drug substance, drug product, and other materials used in our drug candidates are our sole source of supply'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
Erm
5.0
Earnings Timing
5.0
Earnings concerns: 0B/4M

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.2
Macd
0.5
Obv
1.0
Rsi
4.4
Ma Position
9.0
Overbought (RSI 71)Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 3.0<4.5A.R:R 0.4 < 1.5@spotInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 76d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
71 · Overbought
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $33.23Resistance $44.65

Price Targets

$37
$42
A.Upside+6.8%
A.R:R0.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! NEWS_MOD=-1: HOLD_IF_HOLDING → SELL_IF_HOLDING
! Momentum score 3.0/10 — below 4.5 minimum
! Reward/Risk 0.4:1 at current price — below 1.5:1 minimum

Earnings

M
M
M
M
0/4 beats
Next Earnings2026-08-03 (76d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is TGTX stock a buy right now?

Sell if holding. At $39.11, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole-source supply chain. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $36.67. Score 6.3/10, moderate confidence.

What is the TGTX stock price target?

Take-profit target: $41.76 (+5.9% upside). Prior stop was $36.67. Stop-loss: $36.67.

What are the risks of investing in TGTX?

Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole-source supply chain; Thin upside margin: 5.9%.

Is TGTX overvalued or undervalued?

TG Therapeutics, Inc. trades at a P/E of 13.8 (forward 14.5). TrendMatrix value score: 6.5/10. Verdict: Sell.

What do analysts say about TGTX?

15 analysts cover TGTX with a consensus score of 3.9/5. Average price target: $48.

What does TG Therapeutics, Inc. do?TG Therapeutics is a commercial-stage biotech with one FDA-approved product, BRIUMVI (ublituximab-xiiy) for relapsing...

TG Therapeutics is a commercial-stage biotech with one FDA-approved product, BRIUMVI (ublituximab-xiiy) for relapsing forms of MS, commercially launched in the U.S. in January 2023. Ex-U.S. rights are licensed to Neuraxpharm (deal up to $645M plus tiered royalties up to 30%). Pipeline includes subcutaneous ublituximab (Phase 3) and azer-cel CAR-T (Phase 1).

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · INCY (Incyte Corporation) · ARGX (argenx SE) · ADMA (ADMA Biologics Inc) · HALO (Halozyme Therapeutics, Inc.)